Lipid parameters for measuring risk of cardiovascular disease

High-Density Lipoprotein Particle Size and Concentration and Coronary Risk

(2013) Karim El Harchaoui   ANNALS OF INTERNAL MEDICINE

2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations

(2011) Jacques Genest et al.   CANADIAN JOURNAL OF CARDIOLOGY

Comparison between Gradient Gel Electrophoresis and Nuclear Magnetic Resonance Spectroscopy in Estimating Coronary Heart Disease Risk Associated with LDL and HDL Particle Size

(2010) B. J. Arsenault et al.   CLINICAL CHEMISTRY

Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes

(2010) M.-R. Taskinen et al.   DIABETOLOGIA

Lipoprotein(a) as a cardiovascular risk factor: current status

(2010) Børge G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

Lipid assessment, metabolic syndrome and coronary heart disease risk

(2010) Benoit J. Arsenault et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Apolipoprotein(a) Isoforms and the Risk of Vascular Disease

(2010) Sebhat Erqou et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

(2010)   LANCET

Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies

(2010)   LANCET

NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals

(2010) Peter Duewell et al.   NATURE

Disease prevention—should we target obesity or sedentary lifestyle?

(2010) Olivier L. Charansonney et al.   Nature Reviews Cardiology

Population Trends in the Incidence and Outcomes of Acute Myocardial Infarction

(2010) Robert W. Yeh et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparing Trends in BMI and Waist Circumference

(2010) Helen L. Walls et al.   Obesity

Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-CRP as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary Syndromes

(2009) Kausik K. Ray et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

HDL particle size and the risk of coronary heart disease in apparently healthy men and women: The EPIC-Norfolk prospective population study

(2009) Benoit J. Arsenault et al.   ATHEROSCLEROSIS

Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women

(2009) Samia Mora et al.   CIRCULATION

Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices

(2009) J. H. Contois et al.   CLINICAL CHEMISTRY

ApoB versus non-HDL-C: What to do when they disagree

(2009) Allan Sniderman et al.   Current Atherosclerosis Reports

Targets for LDL-lowering therapy

(2009) Allan Sniderman   CURRENT OPINION IN LIPIDOLOGY

Refining Lipoprotein Assessment in Diabetes: Apolipoprotein B Makes Sense

(2009) Om Ganda   Endocrine Practice

The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls

(2009) S. Parish et al.   EUROPEAN HEART JOURNAL

Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction

(2009) Pia R. Kamstrup   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease

(2009) Paul Elliott   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality

(2009)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Major Lipids, Apolipoproteins, and Risk of Vascular Disease

(2009) The Emerging Risk Factors Collaboration*   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Are You Targeting Non–High-Density Lipoprotein Cholesterol?⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.

(2009) Jennifer G. Robinson   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Beyond Low-Density Lipoprotein Cholesterol

(2009) Benoit J. Arsenault et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

(2009) Paul M Ridker et al.   LANCET

C-reactive protein and cardiovascular risk: more fuel to the fire

(2009) S Matthijs Boekholdt et al.   LANCET

C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis

(2009)   LANCET

Age-related differences in inflammatory markers in men: contribution of visceral adiposity

(2009) Amélie Cartier et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease

(2009) Robert Clarke et al.   NEW ENGLAND JOURNAL OF MEDICINE

Usefulness of the Triglyceride–High-Density Lipoprotein Versus the Cholesterol–High-Density Lipoprotein Ratio for Predicting Insulin Resistance and Cardiometabolic Risk (from the Framingham Offspring Cohort)

(2008) William B. Kannel et al.   AMERICAN JOURNAL OF CARDIOLOGY

Overproduction of Very Low–Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome

(2008) Martin Adiels et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

C-Reactive Protein and Parental History Improve Global Cardiovascular Risk Prediction

(2008) Paul M Ridker et al.   CIRCULATION

Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment

(2008) John J.P. Kastelein et al.   CIRCULATION

Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS)

(2008) V. Charlton-Menys et al.   DIABETOLOGIA

VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate

(2008) Michel Farnier et al.   JOURNAL OF LIPID RESEARCH

Lipoprotein Management in Patients With Cardiometabolic Risk

(2008) John D. Brunzell et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial

(2008) Michael Miller et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study

(2008) Matthew J McQueen et al.   LANCET

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetically Elevated C-Reactive Protein and Ischemic Vascular Disease

(2008) Jeppe Zacho et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Association of C-Reactive Protein and CRP Genotype with Coronary Heart Disease: Findings from Five Studies with 4,610 Cases amongst 18,637 Participants

(2008) Debbie A. Lawlor et al.   PLoS One

The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance

(2007) Gijs H. Goossens   PHYSIOLOGY & BEHAVIOR